SCHEMBL30279705

SCHEMBL30279705

CCC1(Cc2ccc(N)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.41
ALDH1A1 P00352 4/20 0.41
TSHR P16473 3/20 0.41
TDP1 Q9NUW8 3/20 0.41
GFER P55789 2/20 0.41
LOXL2 Q9Y4K0 1/20 0.39
CYP19A1 P11511 3/20 0.37
CYP17A1 P05093 1/20 0.37
CYP11A1 P05108 1/20 0.37
TBXAS1 P24557 1/20 0.37
PMP22 Q01453 1/20 0.37
PDE4D Q08499 1/20 0.37
PDE3A Q14432 1/20 0.37
NFKB1 P19838 1/20 0.37
MAPT P10636 2/20 0.36
LMNA P02545 1/20 0.36
MAOB P27338 3/20 0.35
MAOA P21397 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
PSMD14 O00487 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23719251 0.80 IDO1 (0.41) ALDH1A1TDP1MAPTL3MBTL1MAPK1
SCHEMBL14049571 0.79 CYP19A1 (0.41) CYP3A4ALDH1A1TSHRTDP1GFER
SCHEMBL28409253 0.77 ALDH1A1 (0.48) CYP3A4ALDH1A1TSHRTDP1GFER
SCHEMBL8362824 0.75 ALDH1A1 (0.41) CYP3A4ALDH1A1TSHRLOXL2CYP19A1
SCHEMBL19338935 0.74 SKP2 (0.31)
SCHEMBL8945239 0.74 HTR2C (0.43) ALDH1A1
SCHEMBL18015815 0.72 KMT2A (0.44) LOXL2LMNAL3MBTL1KMT2A
SCHEMBL1823450 0.71 MAOB (0.64) CYP3A4ALDH1A1TSHRTDP1GFER
SCHEMBL31589139 0.71 TSHR (0.34) TSHRMEN1KMT2A
SCHEMBL16029497 0.71 MAOA (0.47) ALDH1A1TDP1LMNAMAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240083895-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2024-03-14 US disclosed
US-11618749-B2 Compounds and compositions for treating conditions associated with STING activity IFM DUE, INC. (US) 2023-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11618749-B2 Compounds and compositions for treating conditions associated with STING activity STING1, IRF3, CGAS CYP3A4 4667/4885ALDH1A1 4473/4885TSHR 4546/4885
US-20240083895-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 CYP3A4 4780/4885ALDH1A1 4654/4885TSHR 4487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.